Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Smolle, MA; Schaffler, A; Leithner, A; Van, Praag, VM; Bergovec, M; Szkandera, J; Liegl-Atzwanger, B; Niethard, M; Tunn, PU; Van, De, Sande, M; Andreou, D.
Incidence, treatment and outcome of abdominal metastases in extremity soft tissue sarcoma: Results from a multi-centre study.
J Surg Oncol. 2020; 121(4):605-611
Doi: 10.1002/jso.25856
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Leithner Andreas
- Smolle Maria Anna
- Co-Autor*innen der Med Uni Graz
- Andreou Dimosthenis
- Bergovec Marko
- Liegl-Atzwanger Bernadette
- Szkandera Joanna
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- BACKGROUND AND OBJECTIVES: Abdominal metastases (AM) from soft tissue sarcoma (STS) are rare and prognosis is poor. The aims of the study were to (a) identify risk factors for the development of AM and to (b) investigate the outcome of AM-patients. METHODS: Seven-hundred-sixty-nine STS-patients with localised disease at diagnosis treated at three tumour centres (2000-2016) were retrospectively included (409 males; mean age, 55.6 years [range, 8-96 years]; median follow-up, 4.1 years [interquartile-range, 2.5-6.6 years]). RESULTS: Two-hundred-two patients (26.3%) developed secondary metastases, and 24 of them AM (3.1%). Ten patients developed first AM (FAM) after a mean of 2.4 years and 14 patients late AM (LAM, after being diagnosed with metastases to other sites) after a mean of 2.0 years. Patients with liposarcoma had a significantly higher risk of developing AM (P = .007), irrespective of grading. There was no difference in post-metastasis-survival (PMS) between patients with AM at any time point and those with metastases to other sites (P = .585). Patients with LAM or FAM showed no difference in post-abdominal-metastasis-survival (P = .884). CONCLUSIONS: Survival in patients with AM is poor, irrespective of whether they develop secondarily to other metastases or not. Patients at high-risk of AM (ie, liposarcoma) may be followed-up regularly by abdominal-ultrasound/CT.
- Find related publications in this database (using NLM MeSH Indexing)
- Abdominal Neoplasms - secondary, therapy
- Adolescent - administration & dosage
- Adult - administration & dosage
- Aged - administration & dosage
- Aged, 80 and over - administration & dosage
- Child - administration & dosage
- Extremities - pathology
- Female - administration & dosage
- Humans - administration & dosage
- Incidence - administration & dosage
- Male - administration & dosage
- Middle Aged - administration & dosage
- Retrospective Studies - administration & dosage
- Risk Factors - administration & dosage
- Sarcoma - pathology, therapy
- Young Adult - administration & dosage
- Find related publications in this database (Keywords)
- abdominal metastasis
- soft tissue sarcoma
- survival